Newsletter # 59
• Periods of remission and relapse, as described in human MS patients.
• Relapse phase as severe as in the first attack in untreated RR-MS subjects.
• Dexamethasone therapy reduces the severity of the disease relapse.
• The severity of the disease relapse has been proved to be dependant of the compound administration period.
The RR-MS model proposed by Neurofit provides an interesting and robust assay to evaluate the effect of your compounds on the disease relapse as it mimics the remittance and disease relapse in as in MS patients. Others in-vivo and in-vitro specific Multiple Sclerosis models are also available.
NEUROFIT, your worldwide preferred service provider of validated in-vivo and in-vitro diseases models for drug screening or for evaluating the mechanism of action of your compounds. Please, do not hesitate to consult our website for more information about our animal and neurocellular models, or to consult us directly for a personalized and privileged accompanying on your issues.